Matthew Berger maintains an intellectual property and corporate transactional practice, with a focus on technology, life sciences and media companies and issues. Mr. Berger is experienced in negotiating and drafting agreements for the research and development, licensing, manufacturing, sale, and other commercialization of semiconductors and other hardware and systems, software, biotechnology and pharmaceutical products, medical devices, and medical systems, and multimedia and entertainment products and content. He has negotiated agreements for the protection and licensing and other transfer of a wide range of intellectual property rights, including patents, copyrights, trade secrets, trademarks, and domain names. In addition, Mr. Berger represents technology companies and ventures in entity formation, structuring and negotiating financing, structuring various types of strategic, joint research and development, and other alliances, and mergers and acquisitions.

• Representing Toshiba in its strategic semiconductor wafer manufacturing agreement with Xilinx.
• Representing Fujitsu in its strategic alliance with Sun Microsystems under which Fujitsu will manufacture and sell CPUs, ASICs, and other semiconductor products and the parties will distribute server products and engage in other activities.
• Representing a major Japanese pharmaceutical company in an agreement for the licensing and joint development and commercialization of a pharmaceutical product.
• Representing Sony Computer Entertainment Inc. in its investment in a semiconductor mass production line to build chips with 65nm process using 300mm wafers at IBM's East Fishkill Fab and its joint manufacturing arrangement with IBM.
• Representing Chartered Semiconductor in the establishment of a joint venture with IBM to develop 90nm and 65nm logic processes for foundry chip production on 300mm silicon wafers and to allocate manufacturing capacity between the two foundries.